Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC

Inclusion Criteria

• •1. Histologic diagnosis of non-small cell lung cancer.
• •2. Presence of pathological stage IB, II or IIIA, according to the American Joint Committee on Cancer (AJCC).
• •3. Completely resected tumor at NCC hospital.
• •4. No prior tumor therapy (radiotherapy, chemotherapy, immunotherapy, or any other type of tumor therapy).
• •5. Performance status of 0-1 on ECOG scale.
• •6. At least 18 years old
• •7. Patient compliance that allows adequate follow-up.
• •8. Adequate organ function including the following:Adequate hematologic function: WBC count ≥ 4,000/uL, absolute neutrophil count (ANC) ≥ 1,500/uL, platelet count ≥ 100,000/uL, and hemoglobin ³ 10 gm/dL.Adequate hepatic function: bilirubin ≤ 1.5 x UNL, ALT or AST ≤ 2.5 x UNL.Adequate renal function: creatinine ≤ 1.5mg/dL.
• •9. Signed informed consent from patient or legal representative.
• •10. Patients with reproductive potential must use an approved contraceptive method during and for 3 months after the study. Females with childbearing potential must have a negative urine hCG test within 7 days prior to study enrollment.